

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **The board of directors' report on events of material significance pursuant to Chapter 14, Section 8 of the Swedish Companies Act (2005:551)**

Since the board of directors of EQL Pharma AB, Reg. No. 556713-3425, intends to propose that the extraordinary general meeting resolves on issue of warrants, the board of directors issues the following report on events of material significance.

Since the presentation of the annual report for the financial year 2024/2025, no events of material significance for the company's position have occurred except as set out in the company's interim report for the period 1 April – 30 September 2025 and subsequently issued press releases. The interim report and press releases are available at the company's website, [www.eqlypharma.com](http://www.eqlypharma.com).

---

Lund on 7 January 2026

(Signature page follows)

The Board of Directors of EQL Pharma AB (publ)

Christer Fåhraeus

Anders Månsson

Linda Neckmar

Nikunj Shah

Per Svangren

Raymond De Vré